Tim Dudderidge

Consultant Urological Surgeon

Department of Urology & Oncology, University Hospital Southampton NHS Foundation Trust, Southampton.

Latest Contribution

Map showing global portfolio of randomised trials offering cytoreductive surgery in de novo synchronous metastatic prostate cancer.

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | Basic Science Research, Urologic Oncology

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...